{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01623453",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ANTG-ASC-211"
      },
      "Organization": {
        "OrgFullName": "Anterogen Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)",
      "OfficialTitle": "A Follow-up Study to Evaluate the Sustained Healing Effect the Patients Who Showed Complete Closure of Fistula the Previous ANTG-ASC-210 Study",
      "Acronym": "ANTG"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2012",
      "OverallStatus": "Terminated",
      "WhyStopped": "Difficulty recruiting subjects",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2010"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2014",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "June 8, 2012",
      "StudyFirstSubmitQCDate": "June 17, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 20, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 21, 2016",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 23, 2016",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Anterogen Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This is an open follow-up clinical trial to evaluate a sustained efficacy and safety of ANTG-ASC injection for 4 months (6 months after final dose injection) after Phase II clinical trial."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Perianal Fistula",
          "Primary; Complex"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "crohn's disease",
          "fistula",
          "complex"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Observational",
      "DesignInfo": {
        "DesignTimePerspectiveList": {
          "DesignTimePerspective": [
            "Prospective"
          ]
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "6",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Low dose group",
            "ArmGroupDescription": "Group1. Low dose group",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous adipose derived stem cells(low dose group)"
              ]
            }
          },
          {
            "ArmGroupLabel": "High dose group",
            "ArmGroupDescription": "Group2. High dose group",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous adipose derived stem cells(high dose group)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous adipose derived stem cells(low dose group)",
            "InterventionDescription": "low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Low dose group"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "mesenchymal stem cell, ANTG-ASC, adipose derived stem cell",
                "Group 1: low dose group"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous adipose derived stem cells(high dose group)",
            "InterventionDescription": "high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High dose group"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "mesenchymal stem cell, ANTG-ASC, adipose derived stem cell",
                "Group 2: high dose group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of patients with Sustained efficacy of complete closure of fistula",
            "PrimaryOutcomeDescription": "Proportion of patients with completely closed of fistula (Month 4)",
            "PrimaryOutcomeTimeFrame": "Month 4"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of patients with sustained efficacy of closure of fistula",
            "SecondaryOutcomeDescription": "Proportion of patients with completely closed of fistula (Month 2)\n\nProportion of patients with more than 50% closed of fistula (Month 2, 4)",
            "SecondaryOutcomeTimeFrame": "Month 2, 4"
          },
          {
            "SecondaryOutcomeMeasure": "Evaluation of Fecal Incontinence Score",
            "SecondaryOutcomeDescription": "Evaluation of Fecal Incontinence Score (Wexner Score, Cleveland Clinic Continence Scoring System)",
            "SecondaryOutcomeTimeFrame": "Month 4"
          },
          {
            "SecondaryOutcomeMeasure": "Grade of Investigator's satisfaction",
            "SecondaryOutcomeDescription": "Grade of Investigator's satisfaction (Month 2, 4)\n\nvery satisfied\nsatisfied\nmoderately satisfied\ndissatisfied\nvery dissatisfied",
            "SecondaryOutcomeTimeFrame": "Month 2, 4"
          },
          {
            "SecondaryOutcomeMeasure": "Number of patients with adverse events as a measure of systemic tolerance and physical examinations",
            "SecondaryOutcomeDescription": "systemic tolerance (Month 4) (Biochemistry: Albumin, Alkaline phosphatase, ALT, AST, Bilirubin, Calcium, Chloride, Bicarbonate, Creatinine, Glucose, LDH, Potassium, Sodium, Total protein, Urea nitrogen(BUN), Uric acid / Hematology: Hemoglobin, Hematocrit, Reticulocyte count, complete blood cell count with differential, platelet count, WBC with differential count, ESR, PT/APTT)\nPhysical examination\nPregnancy testing (Month 4)",
            "SecondaryOutcomeTimeFrame": "Month 2, 4"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nthe patients who have participated in ANTG-ASC-210 clinical trial\nthe patients with complete closure at week 8 after last injection in ANTG-ASC-210 trials\nthe patients who submit written informed consents and is able to obey requirements of trials\n\nExclusion Criteria:\n\na patient who has a history of variant Creutzfeldt Jacobs disease or related diseases\na patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue\na patient who has an autoimmune disease\na patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)\na patient who has a symptom of septicemia or active tuberculosis (contain tuberculosis of anus and rectum)\na patient who is pregnant or breast feeding\na patient who is not willing to use effective contraceptive methods during the study\na patient who has inflammatory Bowel disease\na patient who is sensitive to fibrin glue\na patient who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker (who smoked more than 20 cigarettes a day)\na patient who is not able to understand the objective of this study or to comply with the study requirements\na patient who is considered to have a significant disease which can impact the study by investigator\na patient who is considered not suitable for the study by investigator\na patient who had a history of surgery for malignant tumor within the last five years (except carcinoma in situ)\na patient who has multisystemic wasting syndrome (such as tuberculosis, Diabetes, Thyroid disorders, tumor, etc.)\na patient who has taken cytotoxic drugs (such as immunosuppressants, corticosteroid, cytotoxic chemotherapy, anticoagulants, etc.) during long-term",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      },
      "StudyPopulation": "â€¢ the patients with complete closure at week 8 after last injection in ANTG-ASC-210 trials",
      "SamplingMethod": "Non-Probability Sample"
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "KJ Park",
            "OverallOfficialAffiliation": "Seoul National University Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "DS Kim",
            "OverallOfficialAffiliation": "Daehang Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "DaeHang Hospital",
            "LocationCity": "Seoul",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Seoul National University Hospital",
            "LocationCity": "Seoul",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000005402",
            "ConditionMeshTerm": "Fistula"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000020763",
            "ConditionAncestorTerm": "Pathological Conditions, Anatomical"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M5790",
            "ConditionBrowseLeafName": "Crohn Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7684",
            "ConditionBrowseLeafName": "Fistula",
            "ConditionBrowseLeafAsFound": "Fistula",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21672",
            "ConditionBrowseLeafName": "Pathological Conditions, Anatomical",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}